Aura Biosciences, Inc. (AURA) — Financial statements
Income statement, balance sheet, and cash flow for Aura Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 1 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00↑100.0% | -1 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 90↑23.2% | 73↑14.6% | 64↑51.4% | 42↑67.9% | 25 | |
| General & Administrative Expenses | 22↓1.4% | 23↑15.5% | 20↑9.4% | 18↑79.0% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↓1.4% | 23↑15.5% | 20↑9.4% | 18↑79.0% | 10 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 113↑17.3% | 96↑14.8% | 84↑38.8% | 60↑71.0% | 35 | |
| Total Costs & Expenses | 113↑17.3% | 96↑13.1% | 85↑41.0% | 60↑71.0% | 35 | |
| Operating Results | ||||||
| Operating Income | -113↓17.3% | -96↓13.1% | -85↓41.0% | -60↓71.0% | -35 | |
| Depreciation & Amortization | 1↓7.7% | 1↓5.6% | 1↑10.0% | 1↑41.6% | 0.83 | |
| EBITDA | -112↓17.7% | -95↓13.4% | -84↓41.6% | -59↓71.8% | -34 | |
| EBIT | -113↓17.3% | -96↓13.1% | -85↓41.0% | -60↓71.0% | -35 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↓29.7% | 9↑9.8% | 9↑360.7% | 2 | 0.00 | |
| Interest Income | 7↓29.7% | 9↑9.8% | 9↑360.7% | 2↑14238.5% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 7↓27.9% | 9↑6.8% | 9↑469.2% | 2↑153300.0% | -0.00 | |
| Income Before Tax | -106↓22.2% | -87↓13.8% | -76↓29.8% | -59↓66.7% | -35 | |
| Income Tax Expense | 0.11↓3.6% | 0.11↓18.2% | 0.14 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -106↓22.2% | -87↓13.8% | -76↓30.0% | -59↓66.7% | -35 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -106↓22.2% | -87↓13.8% | -76↓30.0% | -59↓66.7% | -35 | |
| Bottom-Line Net Income | -106↓22.2% | -87↓13.8% | -76↓30.0% | -59↓27.2% | -46 | |
| EPS (Basic) | -1.76↓0.6% | -1.75↑9.3% | -1.93↑1.5% | -1.96↓24.1% | -1.58 | |
| EPS (Diluted) | -1.76↓0.6% | -1.75↑9.3% | -1.93↑1.5% | -1.96↓24.1% | -1.58 | |
| Weighted Average Shares | 60↑21.5% | 50↑25.3% | 40↑32.3% | 30↑2.5% | 29 | |
| Weighted Average Diluted Shares | 60↑21.5% | 50↑25.3% | 40↑32.3% | 30↑2.5% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.